Six years after the referendum we can disentangle the evidence and judge the effects on health and care, says Richard Vize.

Sue Ellison, joint MD of OPM (labels and packaging) Group looks at how counterfeiting measures for pharmaceuticals packaging are being affected in a post-Brexit world.

No hint of contrition or constructiveness in article by Lord Frost and Brandon Lewis... just menace.

NICE has a global reputation as a pioneering HTA – but is that influence at risk now that the UK has left the EU? Experts from ICON give us their views on the past, present and future of NICE’s standing on the world stage.

But a closer inspection of the EU-UK Trade and Cooperation Agreement (TCA) renders these statements largely illusory for the pharma sector. While pharma companies grapple with the effects of Brexit, there are undoubtedly a number of ways that the TCA benefits the sector, while leaving significant issues unanswered.

Prime Minister Boris Johnson says he doesn’t want border ‘restrictions’ for medicines, but that’s what his government is doing.

'Trade campaigners have welcomed the release of leaked papers detailing trade talks between the Trump administration and British government officials, which show the US government pushing Britain into as hard a Brexit as possible because they see this as the best way of benefitting the US economy. This comes at the expense of standards, protections and livelihoods in Britain.'

With the NHS under such exceptional pressure during the coronavirus crisis, it’s easy to overlook the fact that the UK’s Brexit transition period ends on December 31. Mark Dayan takes a closer look at how these two challenges for the health service might collide, and says there is a case to err on the side of caution.

The UK must ensure that it retains access to the Single Market, has an open trading regime and maintains a stable regulatory framework with the European Union to minimise the impact of Brexit on the North East economy. This is the key conclusion of ‘Leaving the European Union’, a report by a powerful regional economic group says today.

Britain imports radioactive isotopes to detect and cure cancer. Border chaos at Dover would make them useless in the event of a no-deal Brexit.

The Yellowhammer report suggests medical supplies could be disrupted by a no-deal but a fragile system means it’s more complicated than that.

UK-US trade agreement was always going to be a tough sell. American Ambassador Woody Johnson’s comment to Andrew Marr on Sunday that healthcare would need to be on the table in any future trade talks only served to make agreeing a fully-fledged deal all the more difficult.

US, European, Japanese and Chinese patients could get novel medicines ahead of patients in the UK after Brexit, the CEO of French pharma Ipsen has said in an interview.

So how would a no-deal Brexit affect cancer patients and research?

A transatlantic network of conservative think tanks accidentally published its secret plans to influence US-UK ... Documents outline plans to form an “unprecedented” coalition of hard-Brexit and libertarian think tanks, which will call for Britain to ditch strict EU safety standards – including rules on food and pharmaceuticals – in order to secure a sweeping US-UK trade deal.